|
Clinical samples
|
PB
|
BM
|
|---|
|
Days after the start of administration
|
-1
|
14
|
28
|
42
|
56
|
-1
|
14
|
28
|
42
|
56
|
|---|
|
Arsenic concentrations (ngAs/g)
|
Total plasma
|
5.55
|
47.6
|
56.6
|
55.5
|
18.5
|
7.59
|
53.5
|
72.1
|
88.1
|
20.4
|
| |
HMW-F of plasma
|
1.31
|
20.1
|
25.0
|
27.7
|
9.98
|
1.77
|
26.3
|
44.2
|
62.9
|
14.4
|
| |
LMW-F of plasma
|
4.24
|
27.5
|
31.5
|
27.8
|
8.54
|
5.83
|
27.3
|
27.9
|
25.2
|
5.99
|
- PB and BM aspirations were collected before the treatment start (day -1), and 14, 28, 42, and 56 days after the start of administration. The total arsenic concentrations of HMW-F of PB and BM were determined by ICP-MS as described in "Patient and Methods". The total arsenic concentrations in LMW-F of PB and BM plasma were obtained by subtraction of that in HMW-F from the total arsenic concentrations in PB and BM plasma.
